Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

First Multimodal Embolization Particles Visible on X-ray/Computed Tomography and Magnetic Resonance Imaging

Bartling, Soenke H. MD*†; Budjan, Johannes MD*; Aviv, Hagit PhD; Haneder, Stefan MD*; Kraenzlin, Bettina DMV§; Michaely, Henrik MD*; Margel, Shlomo PhD; Diehl, Steffen MD*; Semmler, Wolfhard MD; Gretz, Norbert MD§¶; Schönberg, Stefan O. MD; Sadick, Maliha MD*

doi: 10.1097/RLI.0b013e318205af53
Original Article

Objectives: Embolization therapy is gaining importance in the treatment of malignant lesions, and even more in benign lesions. Current embolization materials are not visible in imaging modalities. However, it is assumed that directly visible embolization material may provide several advantages over current embolization agents, ranging from particle shunt and reflux prevention to improved therapy control and follow-up assessment. X-ray- as well as magnetic resonance imaging (MRI)-visible embolization materials have been demonstrated in experiments. In this study, we present an embolization material with the property of being visible in more than one imaging modality, namely MRI and x-ray/computed tomography (CT). Characterization and testing of the substance in animal models was performed.

Materials and Methods: To reduce the chance of adverse reactions and to facilitate clinical approval, materials have been applied that are similar to those that are approved and being used on a routine basis in diagnostic imaging. Therefore, x-ray-visible Iodine was combined with MRI-visible Iron (Fe3O4) in a macroparticle (diameter, 40–200 μm). Its core, consisting of a copolymerized monomer MAOETIB (2-methacryloyloxyethyl [2,3,5-triiodobenzoate]), was coated with ultra-small paramagnetic iron oxide nanoparticles (150 nm). After in vitro testing, including signal to noise measurements in CT and MRI (n = 5), its ability to embolize tissue was tested in an established tumor embolization model in rabbits (n = 6). Digital subtraction angiography (DSA) (Integris, Philips), CT (Definition, Siemens Healthcare Section, Forchheim, Germany), and MRI (3 Tesla Magnetom Tim Trio MRI, Siemens Healthcare Section, Forchheim, Germany) were performed before, during, and after embolization. Imaging signal changes that could be attributed to embolization particles were assessed by visual inspection and rated on an ordinal scale by 3 radiologists, from 1 to 3. Histologic analysis of organs was performed.

Results: Particles provided a sufficient image contrast on DSA, CT (signal to noise [SNR], 13 ± 2.5), and MRI (SNR, 35 ± 1) in in vitro scans. Successful embolization of renal tissue was confirmed by catheter angiography, revealing at least partial perfusion stop in all kidneys. Signal changes that were attributed to particles residing within the kidney were found in all cases in all the 3 imaging modalities. Localization distribution of particles corresponded well in all imaging modalities. Dynamic imaging during embolization provided real-time monitoring of the inflow of embolization particles within DSA, CT, and MRI. Histologic visualization of the residing particles as well as associated thrombosis in renal arteries could be performed. Visual assessment of the likelihood of embolization particle presence received full rating scores (153/153) after embolization.

Conclusions: Multimodal-visible embolization particles have been developed, characterized, and tested in vivo in an animal model. Their implementation in clinical radiology may provide optimization of embolization procedures with regard to prevention of particle misplacement and direct intraprocedural visualization, at the same time improving follow-up examinations by utilizing the complementary characteristics of CT and MRI. Radiation dose savings can also be considered. All these advantages could contribute to future refinements and improvements in embolization therapy. Additionally, new approaches in embolization research may open up.

From the *Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany; †Department of Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany; ‡Department of Chemistry, Bar-Ilan University, Ramat-Gan, Israel; §Medical Research Center, University Hospital Mannheim, Heidelberg University, Mannheim, Germany; and ¶Institute for Medical Technology, Heidelberg University, Mannheim, Germany.

Received May 6, 2010; accepted for publication (after revision) November 5, 2010.

Supported by a grant of the German Israel Foundation (61/2007).

Authors Soenke H. Bartling and Johannes Budjan contributed equally.

Reprints: Soenke H. Bartling, MD, Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1–3, 68167 Mannheim, Germany. E-mail:

© 2011 Lippincott Williams & Wilkins, Inc.